Back to search
FDAFDA · Food and drugs·Recall number D-0485-2026

Memantine Hydrochloride Extended-Release, Capsules, 7 mg, 100 Capsules (10 x 10 blister packs), Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268, NDC 0904-6734-61

Published April 22, 2026 · Recall initiated: March 24, 2026

Summary

FDA records drug Class II recall D-0485-2026, published April 22, 2026 and initiated March 24, 2026. Recalling firm: The Harvard Drug Group LLC; Status: Ongoing; Reported quantity: N/A; Lot: Lot # N02425, Exp Date: 05/31/2027. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Dissolution Specifications

What to do

Voluntary: Firm initiated · Letter

Get an email if MEMANTINE HYDROCHLORIDE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
MEMANTINE HYDROCHLORIDE
Manufacturer
The Harvard Drug Group LLC
Distributor
US Nationwide.
Lot
Lot # N02425, Exp Date: 05/31/2027.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Memantine Hydrochloride Extended-Release, Capsules, 7 mg, 100 Capsules (10 x 10 blister packs), Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268, NDC 0904-6734-61 recalled?

Yes. FDA published recall D-0485-2026 on April 22, 2026. Reported hazard: Failed Dissolution Specifications

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: MEMANTINE HYDROCHLORIDE.